Stockreport

Kali Therapeutics Announces Worldwide Exclusive License Agreement with Sanofi for Next-Generation Tri-Specific T-Cell Engager for Autoimmune Diseases [Yahoo! Finance]

Sanofi - American Depositary Shares  (SNY) 
US:NYSE Investor Relations: sanofi.com/en/investors
PDF biologics, today announced that they have entered into a license agreement with Sanofi for a tri-specific T-cell engager, which has the potential to treat a broad range [Read more]